Sleep Tech Expansion Modius Sleep, launched October 2024, targets chronic insomnia with non-invasive neuromodulation. Potential sales opportunity with sleep clinics, insurance-backed programs, VA and military health systems, and large employer wellness initiatives seeking non-pharmacological sleep solutions.

Non-Invasive Advantage FDA-cleared, implant-free neurostimulation positions Neurovalens as a replacement or adjunct to pharmacotherapy for sleep and related disorders. Focus sales conversations with clinicians, hospital procurement, and health systems exploring safer, scalable neuromodulation options.

High Growth Funding Recent financing rounds and awards indicate strong investor confidence and momentum. Leverage this to engage strategic partners, co-development opportunities, and government or private health innovation programs seeking proven growth in health tech.

Global Presence Headquartered in Belfast with a global health-tech footprint and participation in events like CES and Vision 2025. Opportunity to approach international distributors, healthtech integrators, and regional pilots in UK, EU, and US markets.

Strategic Partnerships Product line expansion to Modius Calm and future versions suggests channel opportunities with sleep clinics, primary care networks, employers, and veteran affairs programs. Propose bundled offerings, training, and white-label or referral arrangements to accelerate adoption.